⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
You started semaglutide or tirzepatide with genuine hope. You are injecting weekly, eating less, trying hard — and the scale is barely moving. Or you lost 3–4 kg in the first month and then completely stopped. While most patients lose 10–15% of their body weight on GLP-1 therapy, a meaningful minority do not respond as expected.
Understanding why this happens — and what to do about it — is one of the most important conversations in Indian endocrinology right now, as the number of GLP-1 users in India exceeds hundreds of thousands.
**Consult your healthcare provider before starting any medication.**
There is no single agreed clinical definition, but in practice:
Clinical trials typically define non-response as less than 5% total body weight loss at 12–16 weeks. In the STEP 1 trial of semaglutide 2.4 mg, roughly 14% of participants fell below 5% weight loss even at the highest dose. In the SURMOUNT-1 trial of tirzepatide, approximately 9% at the 15 mg dose were classified as poor responders.
In India, the effective non-response rate may be higher because many patients never reach the target dose due to cost constraints — they remain on sub-therapeutic doses (0.25–0.5 mg semaglutide, 2.5 mg tirzepatide) and are incorrectly labelled "non-responders" when they are actually under-dosed.
Before concluding you are a true non-responder, answer these questions honestly:
If you are on 0.5 mg semaglutide for cost reasons and have never reached 1.0 mg, you are under-dosed — not a non-responder. The conversation with your doctor should be about accessing the therapeutic dose.
Research is ongoing, but several factors appear to predict lower GLP-1 response:
Single nucleotide polymorphisms (SNPs) in the GLP1R gene are associated with variable weight loss response. A 2021 study in Diabetes Care found that patients with certain GLP1R variants lost significantly less weight on semaglutide. These genetic tests are not yet commercially available in India, but the field is moving fast.
Severely insulin-resistant patients (very high HOMA-IR, fasting insulin above 25 mIU/mL) may require longer titration or higher doses before meaningful weight loss begins. The GLP-1 mechanism partially depends on functional beta cell response — severely damaged beta cells may produce a muted response.
GLP-1 reduces appetite, but it does not override learned eating behaviours. Patients who eat in response to emotions, stress, boredom, or social pressure rather than true hunger may compensate for reduced appetite by eating high-calorie, high-palatability foods in smaller quantities. A 500 kcal deficit from appetite reduction can be entirely cancelled by a 200 kcal "reward" snack that previously was not part of the routine.
Several common Indian medications are associated with weight gain and can blunt GLP-1 response:
| Medication | Effect on Weight |
|------------|-----------------|
| Insulin (especially NPH and premix) | Weight gain 2–5 kg |
| Sulfonylureas (glimepiride, glibenclamide) | Weight gain 1–3 kg |
| Olanzapine / other antipsychotics | Weight gain 3–10 kg |
| Corticosteroids (prednisolone, for any condition) | Weight gain, insulin resistance |
| Tricyclic antidepressants | Weight gain |
| Lithium | Weight gain |
| Medroxyprogesterone (DMPA contraceptive) | Weight gain 2–4 kg |
If you are on any of these, discuss with your doctor whether the combination can be adjusted.
Thyroid hormones regulate metabolic rate. Undiagnosed or under-treated hypothyroidism is very common in India (estimated 11% prevalence in adults, per a 2023 ICMR report). Low thyroid function blunts response to GLP-1 therapy and makes weight loss slow or impossible. A TSH and free T4 check before or early in GLP-1 therapy is non-negotiable.
Untreated sleep apnea disrupts cortisol, ghrelin, and leptin cycles in ways that actively promote weight retention. Several studies have shown that GLP-1 response improves significantly after OSA is treated. If you snore loudly, feel unrefreshed after sleeping, or have been told you stop breathing at night, get a sleep study.
Chronic stress, common in urban India, elevates cortisol — which directly promotes visceral fat storage, increases appetite, and counteracts insulin sensitisation. GLP-1 medications have a harder time overriding cortisol-driven biology. Stress management is not a soft suggestion — it is a physiological necessity for GLP-1 to work.
Emerging research suggests that gut microbiome diversity predicts GLP-1 response. Patients with lower Akkermansia muciniphila and Faecalibacterium prausnitzii concentrations tend to respond less well. In India, frequent antibiotic use, low fibre diets, and variable food safety affect microbiome health significantly.
Discuss with your doctor about completing the full titration schedule. Many patients stop at 0.5 mg semaglutide or 5 mg tirzepatide and call themselves non-responders. True non-response requires reaching and maintaining the maximum tolerated dose for 12+ weeks.
**Investigate first:**
**Dietary intensification:**
**Exercise addition:**
1. **Dose increase:** If tolerated, escalate to the next dose level (1.0–2.4 mg semaglutide or 12.5–15 mg tirzepatide)
2. **Switch to tirzepatide:** Patients who do not respond well to semaglutide (pure GLP-1 agonist) sometimes respond significantly better to tirzepatide (GLP-1 + GIP dual agonist). A 2023 head-to-head comparison (SURMOUNT-5) confirmed tirzepatide's greater weight loss efficacy
3. **Add metformin:** For patients with significant insulin resistance, combining metformin with GLP-1 can improve response — metformin improves hepatic insulin sensitivity via a different mechanism
4. **SGLT-2 inhibitor combination:** Empagliflozin or dapagliflozin combined with GLP-1 therapy is showing promising results in Indian patients with residual visceral fat despite weight loss
5. **Reassess bariatric surgery:** For patients with BMI >37.5 kg/m² (or >32.5 with comorbidities) who have genuinely failed 12+ months of adequate GLP-1 therapy, bariatric surgery remains the most durable intervention
Some patients have specific conditions that predict very limited GLP-1 response:
In these cases, GLP-1 therapy may not be the primary solution, and specialised endocrinology and bariatric surgery referral is appropriate.
**Q: Is it possible that I am "immune" to GLP-1 medications permanently?**
True permanent resistance is very uncommon. Most poor responders have at least one modifiable factor — dose, diet, an interfering medication, or untreated comorbidity. Before accepting "non-response," work through the investigation checklist above with your doctor.
**Q: My friend lost 18 kg on Ozempic and I lost only 4 kg. Why?**
GLP-1 response has a strong genetic and physiological component that neither you nor your friend controls. Comparing responses is unhelpful. 4 kg of weight loss may represent more metabolic benefit than 18 kg in a different person — especially if your visceral fat and HbA1c improved significantly.
**Q: Should I try a GLP-1 medication even if I am a likely poor responder?**
Yes, in most cases. Even partial responders benefit from improved blood sugar control, blood pressure reduction, and cardiovascular protection — outcomes that do not require large weight loss to materialise. The medication has value beyond the number on the scale.
**Q: How long should I try before giving up?**
At maximum tolerated dose for a minimum of 16 weeks. Below that threshold, it is too early to conclude non-response. Many patients begin meaningful weight loss at months 3–6 as the dose titration completes.
